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ABSTRACT
Background Although adoptive transfer of CD19- directed 
chimeric antigen receptor (CAR) T- cells (CD19- CAR T- cells) 
achieves high rates of complete response in patients with 
B- cell acute lymphoblastic leukemia (B- ALL), relapse is 
common. Bone marrow (BM) mesenchymal stem/stromal 
cells (BM- MSC) are key components of the hematopoietic 
niche and are implicated in B- ALL pathogenesis and 
therapy resistance. MSC exert an immunosuppressive 
effect on T- cells; however, their impact on CD19- CAR T- 
cell activity is understudied.
Methods We performed a detailed characterization of 
BM- MSC from pediatric patients with B- ALL (B- ALL BM- 
MSC), evaluated their immunomodulatory properties and 
their impact on CD19- CAR T- cell activity in vitro using 
microscopy, qRT- PCR, ELISA, flow cytometry analysis and 
in vivo using a preclinical model of severe colitis and a 
B- ALL xenograft model.
Results While B- ALL BM- MSC were less proliferative 
than those from age- matched healthy donors (HD), the 
morphology, immunophenotype, differentiation potential 
and chemoprotection was very similar. Likewise, both BM- 
MSC populations were equally immunosuppressive in vitro 
and anti- inflammatory in an in vivo model of severe colitis. 
Interestingly, BM- MSC failed to impair CD19- CAR T- cell 
cytotoxicity or cytokine production in vitro using B- ALL 
cell lines and primary B- ALL cells. Finally, the growth of 
NALM6 cells was controlled in vivo by CD19- CAR T- cells 
irrespective of the absence/presence of BM- MSC.
Conclusions Collectively, our data demonstrate that 
pediatric B- ALL and HD BM- MSC equally immunosuppress 
T- cell responses but do not compromise CD19- CAR T- cell 
activity.
BACKGROUND
Acute lymphoblastic leukemia (ALL) is the 
most common malignancy in childhood, 
accounting for ~25% of all childhood cancers.1 
B- cell ALL (B- ALL) represents ~80% of ALL 
and is an aggressive hematologic malignancy 
characterized by the clonal expansion of 
CD19+ B- cell precursors.1 Of special interest 
is the B- ALL harboring chromosomal rear-
rangements of the mixed- lineage leukemia 
gene (MLL- r), which presents unique clinical 
and biological features and has a dismal prog-
nosis compared with other B- ALL.2
B- ALL originates in the bone marrow 
(BM),3 and the BM microenvironment 
(BMM) is particularly important in the patho-
genesis of the B- ALL given the high depen-
dence of leukemic cells on external factors 
for proliferation and survival.4 The BM is also 
the primary site where residual leukemic cells 
survive during standard chemotherapy,5 6 
and is the most frequent location of B- ALL 
relapse.7 Mesenchymal stem/stromal cells 
(MSC) are major components of the BMM 
and are involved in the pathogenesis and 
drug resistance of B- ALL cells during the 
chemotherapy,8–14 underscoring the active 
investigations aimed at unraveling the contri-
bution of BM- MSC to B- ALL cell response to 
treatment.
Adoptive transfer of T- cells engineered 
to express an artificial chimeric antigen 
receptor (CAR) targeting a tumor cell 
surface- specific antigen is a promising new 
approach for cancer immunotherapy. In 
the setting of B- ALL, CAR T- cells targeting 
CD19 have generated unprecedented 
results in multiple clinical trials, and ~50% 
of treated patients are disease- free after 12 
months.15 16 Despite these robust clinical 
responses, however, leukemia relapse after 
treatment is common and remains a major 
challenge for CD19- CAR T- cell therapy.17 An 
intriguing result of CD19- CAR T- cell therapy 
in B- ALL is that MLL- r B- ALL patients show 
lower response rates and higher rates of 
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immune escape.18 The antitumor efficacy and persistence 
of CD19- CAR T- cells within the host depend on complex 
in vivo processes and multicellular interactions and, in 
recent years, it has been extensively demonstrated that 
MSC regulate T- cells by modifying their activation, prolif-
eration and effector functions.19 20 To the best of our 
knowledge, the immunomodulatory properties of pedi-
atric B- ALL- derived BM- MSC in vivo, and their impact on 
CAR T- cell efficacy/resistance in B- ALL remains unex-
plored. Thus, in the present study, we sought to charac-
terize in vitro and in vivo the immunomodulatory effects 
of B- ALL BM- MSC on T- cells and CD19- CAR T- cells, and 
compared them with healthy donors (HD) BM- MSC. A 
better understanding of the interactions between T- cells 
and the B- ALL BMM will help improving the efficiency of 
current immunotherapies in B- ALL.
MATERIALS AND METHODS
Reagents, drugs, antibodies and cell lines
Advanced DMEM, IMDM, RPMI-1640, L- glutamine 
and penicillin- streptomycin (P/S), insulin- transferrin- 
selenium (ITS) were purchased from Gibco/Invitrogen, 
Waltham, Massachusetts, USA. StemSpan SFEM was 
purchased from STEMCELL Technologies StemCell 
Technologies, Vancouver, Canada. Phosphate buffered 
saline was purchased from Merck Life Science SL, Madrid, 
Spain. MSC osteogenic and adipogenic differentiation 
medium were purchased from Promocell, Heidelberg, 
Alemania. Human (h) Stem Cell Factor (SCF), hFMS- like 
tyrosine kinase 3 ligand (FLT3- L), human interleukin-3 
(hIL-3), hIL-7 and hIL-15 were purchased from Miltenyi 
Biotec, Bergisch Gladbach, Germany. Nitro blue tetra-
zolium chloride (NBT), alizarin red, oil red- O, dexameth-
asone, L- phytohemagglutinin (PHA- L) and fetal bovine 
serum (FBS) were purchased from Sigma- Aldrich, St. 
Louis, Missouri, USA. L- asparaginase was purchased from 
Jazz Pharmaceuticals Iberia SL, Barcelona, Spain. Cell-
Trace Violet Cell Proliferation Kit and CellTrace CFSE 
Cell Proliferation Kit were purchased from Fisher Scien-
tific SL, Madrid, Spain. Cell fixation and permeabiliza-
tion Kit was purchased from Nordic- Mubio, Derio, Spain. 
Anti- CD3 (OKT3) and anti- CD28 (CD28.2) monoclonal 
antibodies (mAbs), 7- amino- actinomycin D (7- AAD), 
phycoerythrin (PE) annexin V apoptosis detection kit and 
fluorescein isothiocyanate, PE, peridin chlorophyll, allo-
phycocyanin (APC)-, PE/ cyanine7 (PE/Cy7)-, brilliant 
violet 421 (BV421), BV510)- conjugated mAbs specific for 
human CD3, CD19, CD45, CD13, CD73, CD105, CD90, 
CD31, CD34 and isotype- matched negative control mAbs 
were purchased from BD Bioscience, Franklin Lakes, 
New Jersey, USA. APC- conjugated anti- Nestin mAb was 
purchased from R&D System, Abingdon, UK. The B- ALL 
cell lines SEM and NALM6 were obtained from DSMZ cell 
line bank, Braunschweig, Germany. Luciferase (Luc)/
GFP- expressing- NALM6 cells were kindly provided by RJ 
Brentjens (MSKCC, New York, USA).
Human samples
Peripheral blood (PB) mononuclear cells (PBMC) 
were isolated from buffy coats of healthy volunteers by 
Ficoll- Hypaque gradient centrifugation (GE Healthcare, 
Chicago, Illinois, USA).21 Buffy coats were obtained from 
the Catalan Blood and Tissue Bank (BST) on Institu-
tional Review Board approval (HCB/2018/0030). BM 
B- ALL aspirates were obtained from pediatric patients 
with ETV6/RUNX1 or MLL- r B- ALL (table 1). BM aspi-
rates from age- matched HD were obtained from the BST. 
Human samples were obtained after written informed 
consent in accordance with the Declaration of Helsinki.
Isolation, expansion and characterization of BM-MSC
Mononuclear cells (MC) from BM samples were isolated 
by centrifugation on Ficoll- Paque Plus density gradient. 
MCs were seeded at 2×105 cells/cm2 in advanced DMEM 
with 10% heat- inactivated FBS, L- glutamine and P/S 
(complete advanced DMEM medium) and maintained 
in a humidified atmosphere with 5% CO2 at 37°C 2 
days, after which non- adherent cells were collected and 
frozen and fresh medium was added. Adherent cells at 
>85% confluence were trypsinized and replated at 5×103 
cells/cm2.22 The resulting BM- MSC cultures were main-
tained in complete Advanced DMEM medium. BM- MSC 
cultures were assessed daily for changes in growth rate 
Table 1 Biological and molecular characteristics of HD and B- ALL patients
HD/patient Disease stage Cytogenetic Molecular Age (years) Gender Blasts (%)
HD #1 N.A. N.A. N.A. 9 Female N.A.
HD #2 N.A. N.A. N.A. 10 Female N.A.
HD #3 N.A. N.A. N.A. 7 Male N.A.
Pt #1 Diagnosis t(12;21) ETV6/RUNX1 5 Male 84
Pt #2 Diagnosis t(12;21) ETV6/RUNX1 2 Male 80
Pt #3 Diagnosis t(9;11) MLL/AF9 3 Male 18
Pt #4 Diagnosis t(1;11) MLL/EPS15 1 Female 80
Pt #5 Relapse t(4;11) MLL/AF4 4 Female 81
B- ALL, B- cell acute lymphoblastic leukemia; HD, healthy donors; N.A, not aplicable.
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and morphology. All experiments were performed with 
cells harvested between passage (P)2 and P5.
Growth kinetics of BM- MSC were measured as cumula-
tive Population Doublings at each passage, as described.23 
An equal number of BM- MSC (5×103 cells/cm2) at P1 
were initially plated for each patient/donor; cells were 
then harvested every 5 days, stained with trypan blue, 
counted and re- plated at 5×103 cells/cm2. The procedure 
was repeated until P6.
BM- MSC characterization was performed following 
the guidelines proposed by the International Society for 
Cellular Therapy (ISCT).24 The immunophenotype of 
cultured BM- MSC was assessed by FACS. A total of 1×106 
cells were incubated for 30 min at 4°C in the dark. Data 
acquisition and analysis were performed using a FACS-
Canto- II flow cytometer equipped with FACSDiva soft-
ware (BD Biosciences). Differentiation was evaluated 
by plating BM- MSC in specific differentiation induction 
medium for 3–4 weeks. For osteogenic differentiation, 
BM- MSCs were stained to determine alkaline phospha-
tase (AP) activity using NBT and for calcium deposits 
with alizarin red.25 For adipogenic differentiation, 
BM- MSCs were stained with oil red- O to detect the lipid 
droplets.22 Differentiation capacity was further quanti-
fied by quantitative RT- PCR (qRT- PCR) and RNA was 
isolated from differentiated BM- MSC cultures using the 
Maxwell RSC simplyRNA Cells Kit (Promega, Madison, 
Wisconsin, USA). RT- PCR analysis was conducted using 
the SYBR Green PCR Master Mix (Fisher Scientific SL) 
with primers for specific adipogenic differentiation and 
osteogenic differentiation transcription factors. Analysis 
and mRNA quantification analysis were performed on 
the CFX384 Real- Time System (Bio- Rad Laboratorie, 
Hercules, California, USA). Reactions were performed in 
triplicate and gene expression values were normalized to 
those of HPRT. Gene- specific primer sequences for qRT- 
PCR are listed in online supplementary Table S1.
T-cell proliferation and cytokine secretion
HD and B- ALL BM- MSC were seeded at 1×104 cells/well in 
flat- bottom 96- well plates containing complete Advanced 
DMEM medium at 37°C for 24 hours. The next day, we 
evaluated T- cell proliferation using the CellTrace CFSE 
Cell Proliferation Kit. To do this, PBMCs were labeled 
with 5 µM CellTrace CFSE for 20 min at 37°C and then 
washed three times with RPMI 1640/1% heat- inactivated 
FBS.26 Subsequently, the BM- MSC culture medium was 
removed and CellTrace CFSE- labeled cells were added to 
the adherent BM- MSC culture at a BM- MSC:PBMC ratio 
of 1:5 and 1:10 in RPMI-1640 with10% heat- inactivated 
FBS and P/S (complete RPMI medium) (or plated 
alone), in the absence or presence of PHA- L (1 µg/mL). 
After 3 and 6 days of culture, non- adherent cells were 
collected, washed and stained with an anti- CD3 mAb and 
7- AAD. Viable cells were gated as 7- AAD-. Cell division 
was measured using dye dilution on the CD3+ population 
by FACS and the number of proliferating cells was deter-
mined by gating on the CD3+CFSElow subset.26
Quantification of the proinflammatory cytokines IL-2, 
interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α) 
was measured by ELISA using the OptEIA Human ELISA 
Kit (BD Biosciences) on supernatants from the afore-
mentioned BM- MSC:PBMC cocultures. Unstimulated 
PBMC:BM- MSC cocultures were processed in parallel 
as a control. ELISA determinations were performed in 
triplicate.
In vitro chemoresistance of B-ALL cell lines
HD and B- ALL BM- MSC were seeded at 1×104 cells/well in 
flat- bottom 96- well plates containing complete Advanced 
DMEM medium at 37°C for 24 hours. The next day, the 
BM- MSC culture medium was removed and SEM cells 
(1×105 cells/well) were added to the adherent BM- MSC 
culture at a BM- MSC:SEM ratio of 1:10 in IMDM/10% 
heat- inactivated FBS and P/S, in the absence or presence 
of dexamethasone (10 UI) or L- asparaginase (1 µM). Two 
days after, non- adherent cells were collected, washed and 
stained with an anti- CD19 mAb, 7- AAD and AnnexinV to 
determine cell apoptosis by FACS.27
CD19-CAR vector, lentiviral production, T-cell transduction, 
activation and expansion
We used our clinically validated pCCL second- generation 
lentiviral CD19- CAR backbone, which contains a human 
CD8 transmembrane domain and human 4- 1BB and 
CD3ζ endodomains.28 We incorporated a GFP reporter 
gene after a 2A ribosomal skip sequence at the C- terminal 
CAR sequence to evaluate the transduction efficiency 
and the tracking of CAR expression. CAR- expressing 
viral particles pseudotyped with VSV- G were generated 
by transfection of HEK 293 T cells with pCCL, VSV- G 
and psPAX2 vectors using polyethylenimine (Poly-
sciences, Warrington, Pennsylvania, USA). Supernatants 
were collected at 48 and 72 hours after transfection and 
concentrated by ultracentrifugation.
T- cells were activated by plate- coating with anti- CD3 and 
anti- CD28 mAbs in complete RPMI medium for 2 days 
and were then transduced with a CAR- expressing lenti-
virus at a multiplicity of infection of 10 in the presence of 
hIL-7 and hIL-15 (10 ng/mL).29 T- cells were expanded in 
complete RPMI medium plus hIL-7 and hIL-15 for up to 
6 days. CAR transduction efficiency in T- cells was analyzed 
by FACS.
In vitro CD19-CAR T-cell, cytotoxicity assays and cytokine 
release determination
For cytotoxicity assays, BM- MSCs were seeded at 1×104 
cells/well in flat- bottom 96- well plates containing 
complete Advanced DMEM medium and incubated at 
37°C for 24 hours. The next day, target cells (B- ALL cell 
lines or primary B- ALL cells, 1×105 target cells/well) were 
incubated with CD19- CAR T- cells at an Effector:Target 
(E:T) ratio of 1:1, or alone, for the indicated periods in the 
absence/presence of BM- MSC. Cell lines were cultured in 
RPMI complete medium and primary cells were cultured 
in StemSpan supplemented with 20% heat- inactivated 
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FBS, P/S, ITS, hSCF (100 ng/mL), hFLT3- L (100 ng/
mL), hIL-3 (10 ng/mL) and hIL-7 (10 ng/mL). After 2 
and 6 days of culture, non- adherent cells were collected, 
washed and stained with anti- CD3, anti- CD19, anti- CD10, 
anti- CD22 mAbs and 7- AAD. CAR T- cell- mediated cyto-
toxicity was determined by analyzing the residual living 
(CD10+CD22+7- AAD-) target cells at each time point. BD 
TruCount absolute count tubes (BD Biosciences) were 
used for absolute cell counting. Quantification of the 
pro- inflammatory cytokines IL-2, IFN-γ and TNF-α was 
measured by ELISA using the OptEIA Human ELISA Kit 
(BD Biosciences) on supernatants harvested after 2 days 
of coculture at a 1:1 E:T ratio. ELISA determinations were 
performed in triplicate.
Induction and treatment of experimental acute severe colitis
A well- established experimental mouse model for bowel 
inflammatory disease/acute colitis was employed.30 31 The 
in vivo procedure was approved by the Ethics Committee 
of the Spanish Council of Scientific Research. To 
induce acute colitis, 2,4,6- trinitrobenzene sulfonic acid 
(TNBS, 2 mg; Sigma) in 50% ethanol (100 µL) was 
administered intrarectally in male BALB/c mice aged 
6–8 weeks (n=10/group). Control mice received 50% 
ethanol alone. At 4 hours after TNBS infusion, animals 
were treated intraperitoneally with medium alone, with 
1×106 HD BM- MSCs (n=3) or with 1×106 B- ALL BM- MSC 
(MLL- r B- ALL n=3), resuspended in 200 µl of medium. 
Animals were monitored daily for the appearance of diar-
rhea, body weight loss, and survival. Colitis signs were 
scored based on stool consistency and rectal bleeding by 
a blinded observer using the following scale: 0=normal 
stool appearance, 1=slight decrease in stool consistency, 
2=moderate decrease in stool consistency, 3=moderate 
decrease in stool consistency and presence of blood in 
stools, 4=severe watery diarrhea and moderate/severe 
blooding in stools. At day 9 or immediately after the 
death of the animal, the colons were collected and eval-
uated for macroscopic damage (scale 0–8) based on the 
grade of tissue adhesion, presence of ulceration and wall 
thickness in a blinded fashion by a researcher: ulceration 
(0=normal appearance, 1=focal hyperemia, no ulcers, 
2=ulceration without hyperemia or bowel wall thickening, 
3=ulceration with inflammation at 1 site, 4=two or more 
sites of ulceration and inflammation, 5=major sites of 
damage extending >1 cm along length of colon), adhe-
sions (0=no adhesions, 1=minor adhesions, colon can be 
easily separated from the other tissues, 2=major adhe-
sions); and thickness (maximal bowel wall thickness, in 
mm, measured with a caliper). PB was collected from the 
tail vein (day 4) and by cardiac puncture (day 9) and the 
levels of proinflammatory cytokines were determined 
in sera by specific sandwich ELISA using capture/bioti-
nylated detection antibodies from PreproTech.
In vivo CD19-CAR T cell-mediated cytotoxicity assay
Ten- week- old non- obese diabetic Cg- Prkdcscid Il2rgtm1Wjl/
SzJ (NSG) mice (The Jackson Laboratory, Bar Harbor, 
Maine, USA) were bred and housed under pathogen- free 
conditions. NSG mice were intratibial (IT)- injected with 
1×106 NALM6- Luc+ cells alone or together with 3×105 
BM- MSC,27 followed 4 days later by an intravenous infu-
sion of 4×106 CD19- CAR T- cells. Mice were followed up 
weekly by bioluminescence (BLI) using an in vivo imaging 
system (Lumina III; Perkin- Elmer, Wlatham, Massachu-
setts, USA). Mice were sacrificed at day 15 (controls) 
and day 35 (CAR- treated), and PB and BM samples were 
collected and analyzed by FACS to assess leukemic burden 
and CAR T- cell persistence.
Statistical analysis
Data were plotted as mean±SEM. One- way analysis of vari-
ance with Tukey’s post hoc test was used when three or 
more experimental groups were compared and Student’s 
paired t- test was used when two experimental groups were 
compared. All analyzes were performed with Prism soft-
ware, V.8.0 (GraphPad Prism Software, San Diego, Cali-
fornia, USA).
RESULTS
Expansion and characterization of bona fide BM-MSC from 
pediatric patients with B-ALL
We isolated MSC from BM aspirates of 5 pediatric B- ALL, 
(2 ETV6/RUNX1 and 3 MLL- r), and we compared their 
morphology, immunophenotype, growth kinetics and 
differentiation potential with that of BM- MSC from three 
pediatric HD counterparts using the standardized criteria 
outlined by the ISCT.24 Table 1 shows the main biolog-
ical and molecular/cytogenetic characteristics of B- ALL 
patients and HD. Adherent cell cultures were success-
fully established from all samples using standard MSC 
culture conditions.24 BM- MSC from both groups adhered 
to plastic and showed homogeneous spindle- shaped 
fibroblast- like morphology (figure 1A, online supplemen-
tary figure S1A). FACS analysis at P3 revealed that both 
BM- MSC groups display a bona fide MSC immunophe-
notype positive for CD105, CD90, CD73 and CD13 and 
Nestin, while negative for hematopoietic (CD34 and 
CD45) and endothelial (CD31) cell markers (figure 1B, 
online supplementary figure S1B).22 When we compared 
their expansion potential in vitro under identical culture 
conditions, HD BM- MSC showed a significantly supe-
rior proliferative potential than that of B- ALL BM- MSC 
(figure 1C). We next evaluated the differentiation poten-
tial of P3 BM- MSC cultures by exposing them to adipo-
genic and osteoblastic induction conditions. Both groups 
were similar with regard to adipogenic differentiation, 
measured qualitatively by the formation of lipid droplets 
detected by oil red- O staining; and to osteoblast differen-
tiation, revealed by AP activity staining and by the pres-
ence of calcium deposits detected by Alizarin Red staining 
(figure 1D). Adipogenic and osteoblastic differentia-
tion capacity was also confirmed quantitatively by qPCR, 
which showed a comparable and significant increase in 
the expression of early and late master regulator genes 
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Figure 1 Characterization of BM- MSC from pediatric patients with B- ALL and age- matched HD. (A) Representative phase- 
contrast morphology of BM- MSC. (B) Immunophenotype of expanded BM- MSC at P3. Expression of CD105, CD90, CD73, 
CD13, nestin, CD45, CD34 and CD31 was analyzed by FACS. Shown are representative FACS histograms; gray histograms 
represent isotype- matched negative control mAb and blue histograms represent mAb- specific stained cells. (C) In vitro 
proliferation of BM- MSC calculated as population doubling over six passages. (D, E) Osteogenic and adipogenic differentiation 
capacity of BM- MSC. (D) Left panel, oil red- O staining indicative of adipogenic differentiation capacity. Right panel, Alizarin 
red staining and detection of AP alkaline phosphatase activity with NTB, indicative of osteogenic differentiation capacity. (E) 
Relative quantification of mRNA expression of the adipogenic transcription factors C/EBP-α and PPAR-γ and the osteogenic 
transcription factors BMP2 and RUNX2 by qRT- PCR. Data are shown as mean±SEM. *P<0.05, **p<0.01, ***p<0.001; one- way 
ANOVA with Tukey’s post hoc test. HD BM- MSC n=3 and B- ALL BM- MSC n=5. ANOVA, analysis of variance; B- ALL, B- cell 
acute lymphoblastic leukemia; BM- MSC, bone marrow- mesenchymal stem/stromal cells; HD, healthy donors; NTB, nitro blue 
tetrazolium.
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of adipogenic (CEBPα, PPAR-γ) and osteogenic (BMP2, 
RUNX2) differentiation (figure 1E).
B-ALL BM-MSC immunosuppress T-cell response
MSCs are widely recognized for their immunomodu-
latory potential, including the inhibition of allogenic 
T- cell proliferation and the production of proinflam-
matory cytokines.19 20 We, therefore, monitored PHA- L- 
stimulated T- cell division in the absence or presence of 
BM- MSC in vitro. In line with published findings,32 33 we 
found that HD BM- MSC strongly inhibited T- cell prolifer-
ation in a dose- dependent manner (figure 2A). Of note, 
comparable inhibition of T- cell proliferation was exerted 
by B- ALL BM- MSC (figure 2A). We next analyzed these 
supernatants to test whether BM- MSC also regulate pro- 
inflammatory cytokine secretion. The analysis of super-
natants showed that the levels of IL-2, IFN-γ and TNF-α 
were comparably and significantly lower in HD and 
B- ALL BM- MSC cocultures than in PBMC- only controls 
(figure 2B). Overall, these results show that both HD and 
B- ALL BM- MSC are equally immunosuppressive, as previ-
ously described.32 33
B-ALL BM-MSC exert anti-inflammatory effects in a 
preclinical model of severe acute colitis
Having confirmed the immunosuppressive properties of 
B- ALL BM- MSC in vitro, we wished to test their ability to 
influence T- cell functions in vivo. To do this, we used a well- 
established preclinical model of acute colitis (figure 3A) 
that shares clinical, histopathological and immunological 
features with Crohn’s disease.30 31 As expected, TNBS- 
treated mice developed severe, acute illness character-
ized by substantial (~20%) and sustained body weight 
loss (figure 3B), bloody diarrhea, rectal prolapse and 
pancolitis, accompanied by extensive wasting syndrome 
(figure 3C), which caused 25% mortality over a 9- day 
period (figure 3D). Macroscopic examination of colons 
revealed profound signs of inflammation, hyperemia, 
ulceration and shortening (figure 3E). By contrast, mice 
that were treated with either HD or B- ALL BM- MSC 
Figure 2 In vitro immunomodulatory properties of BM- MSC from pediatric patients with B- ALL and age- matched HD on 
T- cells. (A) Left panel, percentage of proliferating T- cells measured as percentage of CFSE+ T- cells is shown. CellTrace CFSE- 
labeled PBMC (n=3 independent PBMC) was stimulated with PHA- L in the absence/presence of BM- MSC for 6 days at two 
different BM- MSC:PBMC ratios (1:5 and 1:10). Right panel, representative FACS histograms of CellTrace CFSE- labeled PBMC: 
R1 identifies non- proliferating CFSE++ cells, and R2 identifies CFSElow proliferating cells. (B) Secretion of the proinflammatory 
cytokines IL-2, IFN-γ and TNF-α in cell- culture supernatants after 6 days at a BM- MSC:PBMC ratio of 1:10. Data are shown as 
mean±SEM. ***P<0.001, ****p<0.0001; one- way ANOVA with Tukey’s post hoc test. HD BM- MSC n=3 and B- ALL BM- MSC n=5. 
ANOVA, analysis of variance; B- ALL, B- cell acute lymphoblastic leukemia; BM- MSC, bone marrow- mesenchymal stem/stromal 
cells; HD, healthy donors; IFN-γ, interferon-γ; IL-2, interleukin-2; PBMC, peripheral blood mononuclear cell; TNF-α, tumor 
necrosis factor α.
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were largely protected from colitis, as evidenced by a 
significant recovery of their body weight loss within 9 
days (figure 3B), and by the improvement in the wasting 
syndrome and the signs of colon inflammation, which was 
reflected in the significantly lower mortality and colitis 
score as compared with control animals (figure 3C–E). 
In accord with their anti- inflammatory effects, treatment 
with either HD or B- ALL BM- MSC decreased the levels of 
the proinflammatory cytokines TNF-α and IL-6 in the sera 
of colitic mice (figure 3F). Collectively, our findings show 
that B- ALL BM- MSC can suppress inflammation in vivo to 
significantly protect mice against severe acute colitis.
BM-MSC do not compromise CD19-CAR T-cell activity in vitro 
and in vivo
While it is well established the contribution of BM- MSC 
in promoting survival, proliferation and chemotherapy 
resistance in B- ALL8–14 (online supplementary figure S2), 
the potential impact of B- ALL BM- MSC on CD19- CAR 
T- cell therapy has not been explored. Moreover, CAR 
Figure 3 In vivo anti- inflammatory properties of BM- MSC from pediatric patients with B- ALL and HD in a model of acute 
colitis. (A) Scheme of the experimental design. Acute colitis was induced in mice by intrarectal administration of TNBS. After 
4 hours, mice (n=5–10/group) were injected intraperitoneally with medium or with HD or B- ALL BM- MSC. Body weight and 
survival were followed up for 9 days. (B) Daily change in body weight loss relative to day 0 (induction of colon damage). (C) 
Survival over a 9- day follow- up. (D) Colitis score determined at day 3 and 5. (E) Macroscopic damage score was evaluated 
in colons at sacrifice (day 9). (F) Serum levels of IL-6 and TNF-α at day 4 and 9. Data are shown as mean±SEM. ***P<0.001, 
****p<0.0001; one- way ANOVA test with Tukey’s post hoc test. HD BM- MSC n=3 and B- ALL BM- MSC n=3. ANOVA, analysis of 
variance; B- ALL, B- cell acute lymphoblastic leukemia; BM- MSC, bone marrow- mesenchymal stem/stromal cells; HD, healthy 
donors; IL-6, interleukin-6; TNBS, 2,4,6- trinitrobenzene sulfonic acid; TNF-α, tumor necrosis factor α.
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T- cells are likely to experience the same loss of function/
persistence as T- cells in an immunosuppressive B- ALL 
BMM. Consequently, we next explored the influence 
of BM- MSC on CD19- CAR T- cell activity. We first evalu-
ated in vitro the impact of HD and B- ALL BM- MSC on 
CD19- CAR T- cell performance. We generated CD19- CAR 
T- cells following a standard protocol with anti- CD3/anti- 
CD28 plus hIL-7 and hIL-15,29 and studied the effects of 
BM- MSC on CD19- CAR T- cell cytotoxicity against NALM6 
and SEM cells cultured at a 1:1 E:T ratio for 2 and 6 days 
(figure 4A). We found that the number of CD19- CAR- 
resistant NALM6 or SEM cells cultured in the presence 
of either HD or B- ALL BM- MSC was very similar to that 
of target cells exposed to CD19- CAR T- cells alone, a 
non- protective role of BM- MSC on NALM6 (figure 4B) 
and SEM (figure 4C) cell survival in CD19- CAR T- cell 
therapy, at least in vitro. We additionally studied the ex 
vivo impact of B- ALL BM- MSC on CD19 CAR T- cell cyto-
toxicity against autologous primary B- ALL blasts, which 
partially replicates the pathophysiological conditions of 
Figure 4 In vitro cytotoxicity of CD19- CAR T- cells against B- ALL cell lines in the absence/presence of BM- MSC. (A) Achematic 
of the experimental design for assessing the cytotoxicity of CD19- CAR T- cells against NALM6 or SEM B- ALL cell lines in the 
absence or presence of BM- MSC. (B, C) Absolute counts of alive target cells NALM6 (B) and SEM (C) measured by FACS after 
2 and 6 days at 1:1 E:T ratio in the absence/presence of BM- MSC. Data are shown as mean±SEM. ****P<0.0001; one- way 
ANOVA test with Tukey’s post hoc test. HD BM- MSC n=3 and B- ALL BM- MSC n=5. ANOVA, analysis of variance; B- ALL, B- 
cell acute lymphoblastic leukemia; BM- MSC, bone marrow- mesenchymal stem/stromal cells; E:T, Effector:Target; HD, healthy 
donors.
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patients. We performed cytotoxicity assays using B- ALL 
blasts and patient- matched derived BM- MSC from five 
pediatric B- ALL patients (figure 5A). Irrespective of the 
difference in survival of B- ALL primary cells, after 2 days 
of culture the number of alive/resistant primary blasts 
from the five patients after CD19- CAR T- cell treatment 
was very similar in the absence or presence of autologous 
BM- MSC (figure 5B), consistent with the results obtained 
using B- ALL cell lines (figure 4). In addition, we found 
no significant differences in the levels of IL-2, IFN-γ and 
TNF-α in culture supernatants (figure 5C), confirming 
that BM- MSC from pediatric B- ALL do not promote resis-
tance to CD19- CAR T- cells in vitro.
Finally, we evaluated the impact of HD or B- ALL BM- MSC 
on CD19 CAR T- cell cytotoxicity in vivo, using a mouse 
xenograft model with NALM6 cells. To recapitulate the 
interactions between the BM- MSC and leukemic cells, 1×106 
NALM6- Luc+ cells were IT injected into NSG mice alone or 
together with 3×105 HD or B- ALL BM- MSC, followed 4 days 
later by 5×106 CAR- T cells (figure 6A). Mice were followed 
up weekly by BLI. CD19- CAR T- cell- untreated mice showed 
massive leukemic burden and succumbed quickly to the 
disease (figure 6B and C). In contrast, mice treated with 
CD19- CAR T- cells, irrespective of whether they were trans-
planted or not with BM- MSC, similarly controlled the 
disease (figure 6B and C). FACS analysis of leukemic burden 
Figure 5 In vitro cytotoxicity of CD19- CAR T- cells against primary B- ALL blasts in the presence/absence of patient- matched 
BM- MSC. (A) Schematic of the experimental design for assessing the cytotoxicity of CD19- CAR T- cells against primary B- 
ALL blasts in the absence or presence of patient- matched (Pt- m) BM- MSC. (B) Absolute counts of alive primary B- ALL blasts 
measured by FACS after 2 days cytotoxicity assay at a 1:1 E:T ratio in the absence/presence of Pt- m BM- MSC. (C) Secretion 
of IL-2, IFN-γ and TNF-α by CD19- CAR T- cells (n=3 independent PBMC) after 2 days exposure to primary B- ALL cells at a 
1:1 E:T ratio in the absence/presence of Pt- m BM- MSC. Data are shown as mean±SEM B- ALL BM- MSC n=5. B- ALL, B- cell 
acute lymphoblastic leukemia; BM- MSC, bone marrow- mesenchymal stem/stromal cells; CAR, chimeric antigen receptor; E:T, 
Effector:Target; IFN-γ, interferon-γ; IL-2, interleukin-2; PBMC, peripheral blood mononuclear cell; TNF-α, tumor necrosis factor 
α.
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Figure 6 In vivo cytotoxicity of CD19- CAR T- cells in an NALM6 mouse xenograft model in the absence/presence of BM- MSC. 
(A) Schematic of the transplantation of B- ALL cells and BM- MSC followed by CD19- CAR T- cell infusion after 4 days to assess 
in vivo the influence of BM- MSC on CD19- CAR T- cell activity. (B) Leukemic burden monitored weekly (until sacrifice of control 
mice) by BLI. (C) Total RADIANCE quantification (p/sec/cm2/sr) of mice shown in B. (D) Leukemic burden analyzed by FACS in 
PB and BM at the time control mice were sacrificed (day 15). (E) Representative FACS dot plots identifying target cells (red) and 
T- cell persistence (blue) in BM at the time control mice were sacrificed. (F) Long- term (35 days) BLI follow- up of CD19- CAR T- 
cell- treated mice in the absence/presence of BM- MSC. (G) Total RADIANCE quantification (p/sec/cm2/sr) of mice shown in F). 
Each dot represents a mouse. Data are shown as mean±SEM. *P<0.05, ***p<0.001, ****p<0.0001; a paired two- tailed t- test was 
used when two experimental groups were compared, and one- way ANOVA test with Tukey’s post hoc test was used when three 
experimental groups were compared. ANOVA, analysis of variance; B- ALL, B- cell acute lymphoblastic leukemia; BM- MSC, 
bone marrow- mesenchymal stem/stromal cells; CAR, chimeric antigen receptor; E:T, Effector:Target; PB, peripheral blood.
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in PB and BM at day 15 confirmed the BLI data (figure 6D 
and E). All those mice treated with CD19- CAR T- cells with 
or without HD/B- ALL BM- MSCs in which the disease was 
controlled at the time of sacrificing the untreated controls 
(day 15) were followed up to 35 days, and found that neither 
HD nor B- ALL BM- MSC impaired long- term CD19- CAR 
T- cell activity (figure 6F,G). Collectively, neither HD nor 
B- ALL BM- MSCs apparently contribute to CD19- CAR T- cell 
resistance.
DISCUSSION
There is increasing evidence that the BMM can influence 
leukemia progression.34–37 In this context, BM- MSCs are 
considered important players in the BM, promoting prolif-
eration, survival, migration, vascularization and chemoresis-
tance, and suppressing immune cells, all key processes for 
leukemia progression and immune evasion.19 20 36 37 B- ALL 
is malignant proliferation of CD19+ B- cell precursors,1 and 
BM- MSCs have been shown to promote B- ALL progres-
sion and chemoresistance by several mechanisms.4 8–14 38 39 
Here, we obtained BM- MSC from pediatric patients with 
B- ALL and compared their functional and immunological 
characteristics with those of BM- MSC from age- matched 
HD. We show that both HD and B- ALL BM- MSC display 
comparable morphology, immunophenotype and differen-
tiation potential in vitro; however, B- ALL BM- MSCs are less 
proliferative. This is in line with defects in B- ALL BM- MSC 
expansion reported by others.32 33 In addition, we show that 
B- ALL and HD BM- MSC suppress mitogenic T- cell prolifer-
ation by PHA- L in a dose- dependent manner, and block the 
secretion of pro- inflammatory cytokines by T- cells in cocul-
ture. Overall, these data indicate that the typical in vitro 
biological properties of BM- MSC, including their immuno-
suppressive effects, are unchanged in patients with B- ALL, 
which is in agreement with earlier reports.32 33
The in vivo anti- inflammatory properties of BM- MSC 
from patients with hematological malignancies have been 
scarcely investigated.40 In the present study, we describe, for 
the first time to our knowledge, the in vivo anti- inflammatory 
effects of BM- MSC from pediatric patients with B- ALL using 
a preclinical model of acute colitis. TNBS- treated mice 
develop a severe acute illness while mice treated with HD or 
B- ALL BM- MSC are protected against colitis. Also, the levels 
of master pro- inflammatory cytokines in the serum of colitis 
mice treated with HD or B- ALL BM- MSC are diminished. 
Collectively, our results show that HD and B- ALL BM- MSC 
have a similar capacity to dampen inflammation in a well- 
characterized in vivo model.
Given the accumulating evidence that BM- MSCs protect 
B- ALL cells from chemotherapy in vitro,8–14 we confirmed 
that coculturing B- ALL BM- MSC with B- ALL cells reduces 
apoptosis in leukemic cells in response to dexametha-
sone and L- asparaginase, with HD BM- MSC showing a 
similar capacity to protect leukemic cells from chemo-
therapy. Whether B- ALL MSC could protect B- ALL cells 
during CD19- CAR T- cell therapy was, however, not known. 
Thus, we evaluated whether BM- MSC participated in the 
resistance of B- ALL to CD19- CAR T- cell therapy. We found 
that CD19- CAR T- cells can efficiently eliminate both B- ALL 
cell lines and B- ALL primary cells in vitro regardless the 
absence/presence of either HD or B- ALL BM- MSC. More-
over, when we analyzed the proinflammatory cytokines 
secreted in the cocultures of B- ALL blasts with patient- 
matched BM- MSC derived from pediatric B- ALL patients 
we found no significant differences as compared with those 
in the absence of BM- MSC, suggesting that BM- MSC from 
pediatric B- ALL patients do not compromise CD19- CAR 
T- cell efficacy in vitro. These findings concur with a previous 
study by Campana and colleagues.41 We also provide the 
first demonstration, to the best of our knowledge, that in 
vivo HD or B- ALL BM- MSC do not contribute to CD19- CAR 
T- cell resistance using a mouse xenograft model which reca-
pitulates the interactions between the BM- MSC and B- ALL 
cells.
In conclusion, our data show that pediatric B- ALL 
BM- MSC and age- matched HD BM- MSC equally immu-
nosuppressive T- cell response, but do not compromise 
CD19- CAR T- cell activity either in vitro or in vivo, at least 
within the experimental constraints of this study. Although 
this study indicates that specific immunobiological proper-
ties of BM- MSCs do not seem to underlie the resistance of 
B- ALL cells to CD19- CAR T- cells, we must bear in mind that 
our study does not unequivocally assess the contribution 
of the intact BMM, composed of different cell types and 
cellular interactions, to CD19- CAR T- cells mediated cyto-
toxicity. Further in vivo studies using humanized animal 
models are necessary to elucidate the impact of the BMM 
on the response to adoptive cell therapy with CD19- CAR 
T- cells.
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